Integra Lifesciences Holdings Corp (IART) Return on Investment ROI from the third quarter of 2026 to third quarter of 2025 and for the year 2026, average high and low, overall ranking from Sep 30 2026 to Sep 30 2025 - CSIMarket
Integra Lifesciences Holdings's ROI from its third quarter of 2026 to the third quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Integra Lifesciences Holdings's ROI in the third quarter of 2026? Integra Lifesciences Holdings Corp achieved a return on average invested assets (ROI) of 0.41 % in its third quarter of 2026, which is below Integra Lifesciences Holdings's average return on investment, which stands at 1.05%.
ROI has improved compared to -0.23% in the second quarter of 2026, due to net income growth.
Within the Healthcare sector 9 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Sep 30 2026 quarter, so far to 3192, from total ROI ranking in the second quarter of 2026 at 3750.
Integra LifeSciences Aims to Boost Production with New Cutting-Edge Facility in Braintree, Massachusetts, Fuelling Growth Prospects for Investors Integra LifeSciences, a leading global medical technology company, is set to revolutionize its manufacturing capabilities with plans to operationalize a state-of-the-art facility in Braintree, Massachusetts by the first half of 2026. The company s decision to invest in this advanced facility comes as IART shares witnessed an impressive surge of 5.66%, signaling a promising future for investors. Integra LifeSciences commitment to providing innovative medical solutions has been a driving force behind its success in the industry. The decision to establish a new manufacturing facility represents the company s vision for streamlining and expanding its production capabilities, ultimately aiming to meet the growing demand for its top-notch medical technologies.
Integra Lifesciences Holdings Corp, a leading medical technology company, has recently made significant leadership changes and achieved commendable financial results. These developments showcase Integra s commitment to innovation and growth in the healthcare sector. As the company prepares for a transition in its leadership team, investors and stakeholders eagerly anticipate the future trajectory of this influential organization. Leadership Transition Plan: Integra Lifesciences recently announced that Jan De Witte, the current CEO, will retire by the end of 2024. De Witte has been instrumental in driving Integra s success and growth during his tenure. His visionary leadership has positioned the company as a leading provider of advanced medical technologies. Stuart Essig, a seasoned executive, has been appointed as the executive chairman of the Board. Essig brings a wealth of experience and expertise to the role, making him an ideal candidate to oversee the transition and ensure continuity.
Financial Statements
Integra Lifesciences Holdings's III. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
